Image

Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Primary objective:

The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.

  • Compare the social distance and stereotyping by the general population toward individuals with facial involvement by: psoriasis, atopic dermatitis, vitiligo, and alopecia areata.
  • Evaluate demographic factors that describe a greater tendency toward stigmatization.

Description

Basic demographic characteristics (Gender, Age, Employment status, Education level) will be recorded for each patient.

Participants will be asked to observe images depicting faces of individuals with atopic dermatitis, alopecia areata, vitiligo, and psoriasis (generated through artificial intelligence systems). They will be asked to select the individual from those shown that generates the most compassion/pity, disgust, blame/disapproval/disdain, and curiosity for them, analyzing the same emotional responses investigated in a study on stigma toward psoriasis patients.

In addition, each participant will be given a 14-question questionnaire on stigma (analyzing social distance and stereotyping) toward one of the four diseases under investigation (psoriasis, atopic dermatitis, vitiligo, or alopecia areata), selected randomly. For each question, responses will be expressed from 1 to 5, on a Likert scale, with lower scores indicating greater stigma. (Total score between 14 and 70)

Eligibility

Inclusion Criteria:

  • -Patients aged>18 years, both sexes;
  • Signature of written informed consent;

Exclusion Criteria:

  • Patients diagnosed with psoriasis, atopic dermatitis, vitiligo or alopecia areata.
  • Patients with first-degree relatives with psoriasis, atopic dermatitis, vitiligo or alopecia areata
  • Those who for professional or personal reasons have direct knowledge of the diseases in question.

Study details
    Psoriasis (PsO)
    Vitiligo Vulgaris
    Atopic Dermatitis
    Areata Alopecia

NCT06801821

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.